TY - JOUR
T1 - A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice
AU - Tagliamonte, Maria
AU - Petrizzo, Annacarmen
AU - Napolitano, Maria
AU - Luciano, Antonio
AU - Rea, Domenica
AU - Barbieri, Antonio
AU - Arra, Claudio
AU - Maiolino, Piera
AU - Tornesello, Marialina
AU - Ciliberto, Gennaro
AU - Buonaguro, Franco M.
AU - Buonaguro, Luigi
PY - 2016/2/24
Y1 - 2016/2/24
N2 - Background: The tumor immunosuppressive microenvironment represents a major obstacle to an effective tumor-specific cellular immune response. Methods: In the present study, the counterbalance effect of a novel metronomic chemotherapy protocol on such an immunosuppressive microenvironment was evaluated in a mouse model upon sub-cutaneous ectopic implantation of B16 melanoma cells. The chemotherapy consisted of a novel multi-drug cocktail including taxanes and alkylating agents, administered in a daily metronomic fashion. The newly designed strategy was shown to be safe, well tolerated and significantly efficacious. Results: Treated animals showed a remarkable delay in tumor growth and prolonged survival as compared to control group. Such an effect was directly correlated with CD4+ T cell reduction and CD8+ T cell increase. Furthermore, a significant reduction in the percentage of both CD25+FoxP3+ and CD25+CD127low regulatory T cell population was found both in the spleens and in the tumor lesions. Finally, the metronomic chemotherapy induced an intrinsic CD8+ T cell response specific to B16 naturally expressed Trp2 TAA. Conclusion: The novel multi-drug daily metronomic chemotherapy evaluated in the present study was very effective in counterbalancing the immunosuppressive tumor microenvironment. Consequently, the intrinsic anti-tumor T cell immunity could exert its function, targeting specific TAA and significantly containing tumor growth. Overall, the results show that this represents a promising adjuvant approach to significantly enhance efficacy of intrinsic or vaccine-elicited tumor-specific cellular immunity.
AB - Background: The tumor immunosuppressive microenvironment represents a major obstacle to an effective tumor-specific cellular immune response. Methods: In the present study, the counterbalance effect of a novel metronomic chemotherapy protocol on such an immunosuppressive microenvironment was evaluated in a mouse model upon sub-cutaneous ectopic implantation of B16 melanoma cells. The chemotherapy consisted of a novel multi-drug cocktail including taxanes and alkylating agents, administered in a daily metronomic fashion. The newly designed strategy was shown to be safe, well tolerated and significantly efficacious. Results: Treated animals showed a remarkable delay in tumor growth and prolonged survival as compared to control group. Such an effect was directly correlated with CD4+ T cell reduction and CD8+ T cell increase. Furthermore, a significant reduction in the percentage of both CD25+FoxP3+ and CD25+CD127low regulatory T cell population was found both in the spleens and in the tumor lesions. Finally, the metronomic chemotherapy induced an intrinsic CD8+ T cell response specific to B16 naturally expressed Trp2 TAA. Conclusion: The novel multi-drug daily metronomic chemotherapy evaluated in the present study was very effective in counterbalancing the immunosuppressive tumor microenvironment. Consequently, the intrinsic anti-tumor T cell immunity could exert its function, targeting specific TAA and significantly containing tumor growth. Overall, the results show that this represents a promising adjuvant approach to significantly enhance efficacy of intrinsic or vaccine-elicited tumor-specific cellular immunity.
KW - Daily metronomic chemotherapy
KW - Immunotherapy
KW - Treg
UR - http://www.scopus.com/inward/record.url?scp=84959112298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959112298&partnerID=8YFLogxK
U2 - 10.1186/s12967-016-0812-1
DO - 10.1186/s12967-016-0812-1
M3 - Article
AN - SCOPUS:84959112298
VL - 14
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
SN - 1479-5876
IS - 1
M1 - 58
ER -